• linkedin
  • Increase Font
  • Sharebar

    Uro Pipeline: FDA grants priority review to advanced bladder Ca agent

    FDA grants priority review to advanced bladder cancer agent

    The FDA has accepted Genentech’s Biologics License Application (BLA) and granted priority review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant). The BLA submission for atezolizumab is based on results of the IMvigor 210 phase II study, and the FDA will make a decision on approval by Sept. 12, 2016, according to Genentech, which is a member of the Roche group.

     

    First patients enrolled in U.S. IDE trial of BPH treatment

    The first patients have been enrolled in the MedLift U.S. investigational device exemption (IDE) trial of the UroLift System. The MedLift IDE trial will be conducted across eight U.S. sites and is designed to demonstrate safety and effectiveness of the UroLift System for the treatment of patients with BPH who have an obstructive median lobe, which is currently contraindicated in the United States. Obstructive median lobes are present in approximately 5% to 10% of BPH patients who would otherwise be eligible for treatment with the UroLift System, according to manufacturer NeoTract, Inc.

    Next: Company outlines proposed design for phase III trial of BPS/IC agent

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll